Australia markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8067+0.0367 (+4.77%)
At close: 04:00PM EDT
0.8054 -0.00 (-0.16%)
After hours: 07:47PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 137.30M
Enterprise value 278.69M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)299.84
Price/book (mrq)63.84
Enterprise value/revenue 745.17
Enterprise value/EBITDA -2.07

Trading information

Stock price history

Beta (5Y monthly) 2.02
52-week change 3-44.73%
S&P500 52-week change 332.96%
52-week high 32.0500
52-week low 30.5400
50-day moving average 30.9275
200-day moving average 30.9745

Share statistics

Avg vol (3-month) 34.39M
Avg vol (10-day) 34.83M
Shares outstanding 5170.2M
Implied shares outstanding 6170.2M
Float 8106.11M
% held by insiders 114.75%
% held by institutions 145.40%
Shares short (30 Sept 2024) 418.66M
Short ratio (30 Sept 2024) 43.15
Short % of float (30 Sept 2024) 414.69%
Short % of shares outstanding (30 Sept 2024) 410.96%
Shares short (prior month 30 Aug 2024) 415.94M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-42,211.23%

Management effectiveness

Return on assets (ttm)-27.10%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)374k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -151.58M
Net income avi to common (ttm)-162.1M
Diluted EPS (ttm)-1.1900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.23M
Total cash per share (mrq)0.47
Total debt (mrq)212.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.38
Book value per share (mrq)-0.57

Cash flow statement

Operating cash flow (ttm)-181.8M
Levered free cash flow (ttm)-98.53M